Table of Contents
Executive summary
- The macroeconomic environment in China
- The Chinese healthcare system
- Chinese hospital market analysis
- Key players in the Chinese hospital pharmaceutical market
Chapter 1 Scope and methodology
- Scope
- Methodology
- IMS caveat
Chapter 2 The macroeconomic environment in China
- Summary
- Introduction
- Population profile
- Disease burden
- Demographic factors in the Chinese healthcare system
- Age profile
- Modernization
- Affordability
- Economic landscape
- Healthcare spending
- Key events in China' s economic landscape
- The increased importance of domestic consumption
- China' s economic growth in 2009 could be much worse than expected
- Measures that could mitigate the economic downturn in China
- Environmental landscape
Chapter 3 The Chinese healthcare system
- Summary
- Introduction
- Recent developments in the healthcare sector
- All villages in China to have a medical clinic in the next three years
- The Chinese government will deal with rural medical staff shortages
- Amended healthcare reforms will strengthen the healthcare system in
urban and rural areas
- An essential drugs list (EDL) to curb the rising drug prices in China
- The Chinese MOH takes responsibility for food safety monitoring
- Chinese drug regulatory system
- Intellectual property protection
- Pricing and reimbursement
- The Chinese drug approval system
- Drug advertising in China
- The drug distribution system
- The future of Chinese healthcare reforms
- Chinese biotech developments
- Improving scientific base
- Chinese biosimilar market
- Major biosimilars in China
Chapter 4 Chinese hospital market analysis
- Summary
- Introduction
- The Chinese hospital pharmaceutical market
- Traditional Chinese medicines (TCMs)
- The domestic Chinese pharmaceutical market
- Multinationals versus domestic companies
- Investment in China based R&D
- Therapy area analysis
- Therapy area sales forecast
- Leading products dynamics
Chapter 5 Key players in the Chinese hospital pharmaceutical market
- Summary
- Introduction
- Competitive positioning of the top pharmaceutical players in hospital
- settings
- Detailed analysis of key players in the Chinese hospital pharmaceutical
- market
- Pfizer
- Overview
- Sales focus by leading therapeutic area
- Marketed product portfolio
- Pfizer' s pipeline focus
- Strategic growth analysis
- AstraZeneca
- Overview
- Sales focus by leading therapeutic area
- Marketed product portfolio
- AstraZeneca' s pipeline focus
- Strategic growth analysis
- Bayer
- Overview
- Sales focus by leading therapeutic area
- Marketed product portfolio
- Bayer' s pipeline focus
- Strategic growth analysis
- Sanofi-Aventis
- Overview
- Sales focus by leading therapeutic area
- Marketed product portfolio
- Sanofi-Aventis' s pipeline focus
- Strategic growth analysis
- Roche
- Overview
- Sales focus by leading therapeutic area
- Marketed product portfolio
- Roche' s pipeline focus
- Strategic growth analysis
- Novartis
- Overview
- Sales focus by leading therapeutic area
- Marketed product portfolio
- Novartis' s pipeline focus
Chapter 6 Appendix
- Anatomical Therapeutic Classification (ATC)
- A: Alimentary tract and metabolism
- B: Blood and blood-forming organs
- C: Cardiovascular system
- D: Dermatologicals
- G: Genito-urinary system and sex hormones
- H: Systemic hormonal preparations
- J: General anti-infectives systemic
- K: Hospital solutions
- L: Antineoplastic and immunomodulating agents
- M: Musculo-skeletal system
- N: Nervous system
- P: Parasitology
- R: Respiratory system
- S: Sensory organs
- T: Diagnostic agents
- V: Various
- Glossary
- Index
List of Figures
- Figure 2.1: Population demographics in China, 2008
- Figure 2.2: Comparison of healthcare expenditures across seven emerging
pharmaceutical markets
- Figure 3.3: Drug approval process in China
- Figure 3.4: Drug distribution channels in China
- Figure 4.5: Top 10 sub-therapy area sales in the Chinese hospital
pharmaceutical market, 2008
- Figure 5.6: Pfizer' s Chinese market sales by therapy area, 2008
- Figure 5.7: AstraZeneca' s Chinese market sales by therapy area, 2008
- Figure 5.8: Bayer' s Chinese market sales by therapy area, 2008
- Figure 5.9: Sanofi-Aventis' s Chinese market sales by therapy area, 2008
- Figure 5.10: Roche' s Chinese market sales by therapy area, 2008
- Figure 5.11: Novartis' s Chinese market sales by therapy area, 2008
List of Tables
- Table 2.1: Forecast epidemiology of risk factors/common disorders in
China, 2008 14
- Table 3.2: Major biosimilars in China
- Table 3.3: Patent expirations of top selling innovator biologics
- Table 4.4: Chinese hospital pharmaceutical market by therapy area sales
growth, 2008
- Table 4.5: Chinese hospital pharmaceutical market sales forecast by ATC
code, 2008 14
- Table 4.6: Leading products in the Chinese hospital pharmaceutical market,
2008
- Table 4.7: Leading products sales forecast, 2008 14
- Table 5.8: Leading players in the Chinese hospital pharmaceutical market,
2008
- Table 5.9: Pfizer' s leading products in the Chinese hospital
pharmaceutical market, 2008
- Table 5.10: AstraZeneca' s leading products in the Chinese hospital
pharmaceutical market, 2008
- Table 5.11: Bayer' s leading products in the Chinese hospital
pharmaceutical market, 2008
- Table 5.12: Sanofi-Aventis' s leading products in the Chinese hospital
pharmaceutical market, 2008
- Table 5.13: Roche' s leading products in the Chinese hospital
pharmaceutical market, 2008
- Table 5.14: Novartis' s leading products in the Chinese hospital
pharmaceutical market, 2008
|
Related Report
|
View Cart
